Endo USA Inc., a Keenova Therapeutics Company
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Endo USA Inc., a Keenova Therapeutics Company sits in the top decile of US sponsors by registered trial count (#334 of 15,742 sponsors by registered trial count).
Endo USA Inc., a Keenova Therapeutics Company: 61 sponsored US clinical trials, none currently recruiting.
Endo USA Inc., a Keenova Therapeutics Company sponsors 61 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 46 completed. 29 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage).
Top-decile sponsor footprint
Endo USA Inc., a Keenova Therapeutics Company ranks in the top decile of sponsors by registered trial count (#334 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
46 of 61 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
61 total, page 1 of 2
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
NCT06169319
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
NCT05873595
Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture
NCT05877066
Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity
NCT05249257
Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
NCT05152173
Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
NCT04677712
Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)
NCT04680156
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
NCT04580303
Safety and Efficacy of EN3835 in Participants With Frozen Shoulder
NCT04496167
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
NCT04456296
Histopathology Following CCH Injection
NCT04236635
Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women
NCT04209530
Real World CCH Study in Adult Females With Cellulite
NCT04170296
Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers
NCT04093050
Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
NCT03893890
Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP
NCT03675685
Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
NCT03632993
Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
NCT03446781
Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
NCT03428750
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
NCT03329989
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
NCT02942160
Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
NCT02687451
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
NCT02724644
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
NCT02298829
CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment
NCT01715467
Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures
NCT01674634
Retreatment of Recurrent Dupuytren's Contractures
NCT01498640
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
NCT01430169
Administration of Two Injections for Multiple Dupuytren's Contractures
NCT01407068
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
NCT01310803
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT01314664
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
NCT01295060
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
NCT01210352
A Study of AA4500 in Men With Peyronie's Disease
NCT01243411
Time to Eugonadal Range, Time to Steady State and Drying Time
NCT01228071
Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859
NCT00954746
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
NCT00884715
Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.
NCT00801398
A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering
NCT00830154
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects
NCT00765856
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
NCT00765323
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
NCT00755222
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
NCT00574860
Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
NCT00528840
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
NCT00528606
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
NCT00465959
Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee
NCT00589979
Exploratory Study of Pagoclone in Men With Premature Ejaculation.
NCT00370981
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
NCT00467870
Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome
NCT00266214
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 19 |
| Phase 3 | 22 |
| Phase 4 | 7 |
How the Endo USA Inc., a Keenova Therapeutics Company archive is shaped
61 indexed studies, none listed as recruiting (0% open); 46 completed (75%).
Phase mix: 29 late (III/IV) vs 23 early (I/II) (balanced across stages).
Therapeutic area indexing for this sponsor is limited in the public registry.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Endo USA Inc., a Keenova Therapeutics Company: archived-pipeline peers nationwide
Peers matched on 61 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Endo USA Inc., a Keenova Therapeutics Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 61 archived trials
- NICHD Neonatal Research Network · 61 trials · 7% recruiting
- Oregon Research Institute · 62 trials · 8% recruiting
- Power Life Sciences · 62 trials · 2% recruiting
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 60 trials · 22% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Endo USA Inc., a Keenova Therapeutics Company page
61 registered trials is a research-attention snapshot, not an endorsement of Endo USA Inc., a Keenova Therapeutics Company or any single study.
- None of Endo USA Inc., a Keenova Therapeutics Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Endo USA Inc., a Keenova Therapeutics Company pipeline card: 61 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.